Fritextsökning
Artiklar per år
Innehållstyper
-
Sophion etablerar sig i Japan
Öppnar nytt sälj och supportkontor som ska ledas av en ledande japansk elektrofysiolog.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Biovitrum sells UK part
Biovitrum will soon spin-out a British subsidary
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
Apoteket gets new vice CEO
The Swedish government company Apoteket has recently appointed a vice CEO.
-
Oasmia gets a confirmation
FDA has granted Oasmia an expedited review status for Paclical Vet.
-
Respiratorius hunts millions
The biopharmaceutical company Respiratorius has got a new CEO, who starts a public new share issue to catch almost SEK ten million.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Harmony prevents dementia
People who are active, outgoing and relaxed may be less likely to develop dementia, according to a new study from Karolinska Institutet.
-
Positive combined cancer therapy
Topotarget announces positive data with new treatment against colorectal cancer.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Swedish multi competent machine soon launched
The Swedish company Biosensor will launch new equipment able to detect twelve different narcotics and explosives simultaneously.
-
Pharma is a safe market
Pharma is the best industry to invest in. That states leaders from risk capital companies, interviewed by the Economist Intelligence Unit.
BREAKING